The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02A | Opioids | |
| 4 | N02AE | Oripavine derivatives |
| Code | Title | |
|---|---|---|
| N02AE01 | Buprenorphine |
| Active Ingredient | Description | |
|---|---|---|
| Buprenorphine |
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the ÎŒ (mu) and Îș (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the ÎŒ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BUTEC Transdermal patch | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| BUTRANS Transdermal system | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| NORSPAN Patch | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| RELETRANS Transdermal patch | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| SUBOXONE Sublingual tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TEMGESIC Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TEMGESIC Sublingual tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| TRANSTEC Transdermal patch | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
